Search Medical Condition
Please enter condition
Please choose location

Sanchinarro, Spain Clinical Trials

A listing of Sanchinarro, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (435) clinical trials

Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. Up to 30 subjects may be enrolled in the study. The first 18 subjects may be of the following PTCL sub-types: PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell ...

Phase

1.01 miles

Learn More »

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess ...

Phase

1.01 miles

Learn More »

Study of Plitidepsin (Aplidin ) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of Plitidepsin (Aplidin) to determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM), to determine the efficacy of the combination plitidepsin/bortezomib/dexamethasone, to evaluate the safety and tolerability of ...

Phase

1.01 miles

Learn More »

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has ...

Phase N/A

1.01 miles

Learn More »

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

This is an open-label, dose-finding, safety, pharmacokinetics (PK), and evidence-of-activity study of GDC-0927 in postmenopausal women with locally advanced or metastatic Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 (HER2) breast cancer. The study will be conducted in two parts: Dose escalation and Dose expansion. During dose escalation, ...

Phase

1.01 miles

Learn More »

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

Phase

1.01 miles

Learn More »

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD or Pembrolizumab in Adults With FRa + Adv. EOC Primary Peritoneal Fallopian Tube or Endometrial Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

1.01 miles

Learn More »

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for safety and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be determined. Sym015 will be given at different dose levels on an every second week (Q2W) dosing schedule. Each patient will be given one ...

Phase

1.01 miles

Learn More »

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

The study was redesigned to expand the number of patients analyzed during the Phase 1b stage of the study to determine a safe and effective dose of AG-120 administered with azacitidine for future studies. The Phase 1b (AG-120 expansion) stage will evaluate the safety, tolerability, and clinical activity of oral ...

Phase

1.01 miles

Learn More »